Business Wire

European Parliament - E-Cig: a Potential Step Forward for European Health According to LIAF – Lega Italiana Anti Fumo

Share

The following is a statement from LIAF – Lega Italiana Anti Fumo:

Use of e-cigarettes in the world is growing continuously. However, Europe is falling behind. It is essential that Europe exploits the potential of this technology to reduce the impact of smoking on European Public Health. For this reason, the Italian Anti-Smoking League (Lega Italiana Anti Fumo - LIAF), hosted by MEP Giovanni La Via (former Chair of the ENVI Committee), is bringing experts and policymakers to the European Parliament to discuss the benefits of electronic cigarettes. The event takes place on 20 March 2018 at 12.30 p.m. and will allow experts to exchange views on the potential of e-cigarettes to help reshape European health.

Though this is a very important public health issue, the discussion has been absent from the European agenda. With cigarettes killing more than half a million smokers a month globally and almost 6 million Europeans now using e-cigarettes to move away from smoking, providing scientific evidence to shift the balance from an ‘abstinence-only’ agenda to a harm reduction strategy is vital in bringing down smoking deaths.

Europe is at a crossroads in the fight against smoking. A growing body of evidence shows that there is a huge opportunity for public health in promoting the use of e-cigarettes to help people stop smoking. Health policymakers in Europe have a duty to provide the public with all of the facts on e-cigarettes, and to provide the best regulatory environment to help smokers quit completely.”Giovanni La Via, Member of European Parliament (EPP, Italy).

Recent reports have led key public health institutions to take a positive stance on e-cigarettes. Well-respected bodies, such as Public Health England (PHE), Cancer Research UK and Action on Smoking and Health (ASH), recognise the potential of e-cigarettes to reduce the health effects of smoking. PHE’s recent report on e-cigarettes (February 2018) concludes that vaping or using e-cigarettes are 95% safer than smoking tobacco. Moreover, the report shows that while smoking rates among young people continue to fall, there is no evidence that e-cigarettes are a gateway to smoking. The same research found that e-cigarettes are used almost exclusively by those who have already smoked.

This event will be an important opportunity for MEPs and speakers to work together, share scientific perspectives and establish tools that can successfully be exploited in the drive to reduce smoking in Europe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LIAF – Lega Italiana Anti Fumo
Valeria Nicolosi, (+39) 095.3781581
info@liaf-onlus.org

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

HiddenA line styled icon from Orion Icon Library.Eye